MFAMEDIUM SIGNALFINANCIAL10-K

MFA's operating cash flow declined meaningfully while interest expenses grew substantially, though the company maintained profitability with higher net income.

The substantial reduction in operating cash flow combined with significantly higher interest expenses suggests increased financing costs are pressuring cash generation, likely reflecting the challenging interest rate environment for mortgage REITs. However, the company's ability to grow net income despite these headwinds indicates effective asset management and potentially beneficial positioning in higher-rate markets.

Comparing 2026-02-20 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

MFA's financial profile shows mixed signals with meaningfully reduced operating cash flow and substantially higher interest expenses reflecting the pressured operating environment for mortgage REITs. However, net income grew notably despite these headwinds, while the balance sheet expanded with total assets increasing to $13.0B and liabilities rising proportionally. The company maintained adequate liquidity though cash positions declined modestly, and capital expenditures dropped to minimal levels suggesting a focus on preserving cash flow.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97.5%
$12.0M$300K

Capex reduced 97.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
+65.8%
$258.8M$429.1M

Interest expense surged 65.8% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-61.9%
$200.1M$76.2M

Operating cash flow fell 61.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
+48.2%
$119.3M$176.8M

Net income grew 48.2% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-37.1%
$338.9M$213.2M

Cash declined 37.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+17.3%
$9.6B$11.2B

Liabilities increased 17.3% — monitor debt-to-equity ratio and interest coverage.

Total Assets
Balance Sheet
+14.3%
$11.4B$13.0B

Asset base grew 14.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-20
ADDED
On February 17, 2026, the registrant had a total of 102,093,862 shares of Common Stock outstanding.
Changes in and Disagreements W ith Accountants on Accounting and Financial Disclosure 125 Report of Independent Registered Public Accounting Firm 66 Consolidated Balance Sheets at December 31, 202 5 and December 31, 202 4 68 Item 9A.
Other Information 127 Consolidated Statements of Operations for the years ended December 31, 202 5 , 202 4 and 202 3 69 Item 9C.
Executive Compensation 127 Consolidated Statements of Changes in Stockholders Equity for the years ended December 31, 202 5 , 202 4 and 202 3 71 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 128 Consolidated Statements of Cash Flows for the years ended December 31, 202 5 , 202 4 and 202 3 73 Item 13.
+7 more — sign up free →
REMOVED
On February 14, 2025, the registrant had a total of 102,523,820 shares of Common Stock outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 126 Report of Independent Registered Public Accounting Firm 66 Financial Statements: Item 9A.
Controls and Procedures 126 Consolidated Balance Sheets at December 31, 2024 and December 31, 2023 68 Item 9B.
Directors, Executive Officers and Corporate Governance 128 Consolidated Statements of Comprehensive Income/(Loss) for the years ended December 31, 2024, 2023 and 2022 70 Item 11.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 129 Consolidated Statements of Changes in Stockholders Equity for the years ended December 31, 2024, 2023 and 2022 71 Item 13.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →